Get the Stockscreener App
0.9315
0.91%
-0.0086
Immunic Inc stock is traded at $0.9315, with a volume of 668.08K.
It is down -0.91% in the last 24 hours and up +34.92% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$0.9401
Open:
$0.9
24h Volume:
668.08K
Relative Volume:
0.38
Market Cap:
$89.25M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.4415
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
-16.83%
1M Performance:
+34.92%
6M Performance:
-4.46%
1Y Performance:
-33.46%
1-Day Range:
$0.8901
$0.932
1-Week Range:
$0.8901
$1.18
52-Week Range:
$0.561
$2.11
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.9315 | 90.08M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Why is Immunic Inc. stock attracting strong analyst attentionBreakout Stocks Opportunities That Work - jammulinksnews.com
What institutional investors are buying Immunic Inc. stockBreakout Stocks Tips That Work - jammulinksnews.com
Why Immunic Inc. stock attracts strong analyst attentionDaily Chart Pattern Stock Forecast Shows Bullish Setup - beatles.ru
What is the risk reward ratio of investing in Immunic Inc. stockGame-changing returns - jammulinksnews.com
How Immunic Inc. stock performs during market volatilityShort Term Trading Opportunity Watch Sees Shift - beatles.ru
What is the dividend policy of Immunic Inc. stockBuild wealth with long-term growth strategies - jammulinksnews.com
What are analysts’ price targets for Immunic Inc. in the next 12 monthsCapitalize on emerging market trends - jammulinksnews.com
Is it the right time to buy Immunic Inc. stockFree Predictions - jammulinksnews.com
Should I hold or sell Immunic Inc. stock in 2025Triple-digit profit margins - jammulinksnews.com
What is Immunic Inc. company’s growth strategyBreakthrough profit margins - jammulinksnews.com
When is Immunic Inc. stock expected to show significant growthIdentify safe investments with exceptional yields - jammulinksnews.com
Is Immunic Inc. a growth stock or a value stockAchieve rapid portfolio growth with smart picks - jammulinksnews.com
What are the technical indicators suggesting about Immunic Inc.Free Consultation - jammulinksnews.com
Immunic, Inc.'s (NASDAQ:IMUX) market cap touched US$103m last week, benefiting both individual investors who own 55% as well as institutions - simplywall.st
Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial - Insider Monkey
What drives Immunic Inc. stock priceRapid return acceleration - Autocar Professional
What analysts say about Immunic Inc. stockRecord-breaking gains - PrintWeekIndia
How Immunic Inc. stock reacts to Fed policy changesPowerful profit generation - jammulinksnews.com
Immunic Inc. Stock Analysis and ForecastRapid growth opportunities - Autocar Professional
How high can Immunic Inc. stock price go in 2025Accelerated earnings growth - jammulinksnews.com
Is Immunic Inc. a good long term investmentBreakthrough profits - PrintWeekIndia
Immunic, Inc. shares fall 2.01% premarket after AstraZeneca's immune disorder drug succeeds in late-stage trial. - AInvest
12 Best Penny Stocks Under $1 to Buy Now - Insider Monkey
World Brain Day: Immunic targets MS with new therapy - Proactive financial news
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunic Inc Stock (IMUX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tardio Jason | President and COO |
Jun 05 '25 |
Buy |
0.79 |
12,512 |
9,884 |
12,512 |
| Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
| Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
| Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
| Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
| Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
| Rudick Richard Alan | Director |
Nov 12 '24 |
Buy |
1.15 |
87,300 |
100,369 |
87,300 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):